Hancock Whitney Corp Vertex Pharmaceuticals Inc Transaction History

Hancock Whitney Corp

$2.88 Billion
Q1 2024

A detailed history of Hancock Whitney Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hancock Whitney Corp holds 2,792 shares of VRTX stock, worth $1.32 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

2,792

Previous 2,691 3.75%

Holding current value

$1.32 Million

Previous $1.09 Million 6.67%

% of portfolio

0.04%

Previous 0.04%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 16, 2024	BUY	$407.69 - $446.08 $41,176 - $45,054	101 Added 3.75%	2,792 $1.17 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $31,899 - $38,193	-93 Reduced 3.34%	2,691 $1.09 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $11,159 - $11,961	33 Added 1.2%	2,784 $968,000
Q2 2023 Nov 13, 2023	BUY	$314.42 - $351.91 $65,399 - $73,197	208 Added 8.18%	2,751 $968,000
Q2 2023 Aug 10, 2023	BUY	$314.42 - $351.91 $65,399 - $73,197	208 Added 8.18%	2,751 $968,000

Q1 2023 Nov 13, 2023	BUY	$283.23 - $323.1 $205,341 - $234,247	725 Added 39.88%	2,543 $801,000
Q1 2023 May 16, 2023	BUY	$283.23 - $323.1 $205,341 - $234,247	725 Added 39.88%	2,543 $801,000
Q4 2022 Nov 13, 2023	SELL	$285.76 - $321.48 $266,614 - $299,940	-933 Reduced 33.91%	1,818 $525,000
Q4 2022 Feb 03, 2023	BUY	$285.76 - $321.48 $571 - $642	2 Added 0.11%	1,818 $525,000
Q3 2022 Oct 26, 2022	BUY	$273.83 - $305.53 $4,928 - $5,499	18 Added 1.0%	1,816 $526,000
Q2 2022 Aug 08, 2022	SELL	$234.96 - $292.55 $68,138 - $84,839	-290 Reduced 13.89%	1,798 $507,000
Q1 2022 May 12, 2022	BUY	$221.42 - $260.97 $22,363 - $26,357	101 Added 5.08%	2,088 $545,000
Q4 2021 Jan 25, 2022	BUY	$177.01 - $223.45 $4,248 - $5,362	24 Added 1.22%	1,987 $436,000
Q3 2021 Nov 04, 2021	BUY	$181.39 - $202.99 $4,353 - $4,871	24 Added 1.24%	1,963 $356,000
Q2 2021 Aug 09, 2021	SELL	$187.49 - $221.1 $21,186 - $24,984	-113 Reduced 5.51%	1,939 $391,000
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $362,906 - $423,016	-1,753 Reduced 46.07%	2,052 $441,000
Q4 2020 Feb 09, 2021	SELL	$207.01 - $276.09 $7,245 - $9,663	-35 Reduced 0.91%	3,805 $899,000
Q3 2020 Nov 05, 2020	SELL	$255.65 - $303.1 $112,486 - $133,364	-440 Reduced 10.28%	3,840 $1.05 Million
Q2 2020 Jul 30, 2020	SELL	$225.48 - $295.8 $12,401 - $16,269	-55 Reduced 1.27%	4,280 $1.24 Million
Q1 2020 May 08, 2020	BUY	$199.77 - $247.81 $26,968 - $33,454	135 Added 3.21%	4,335 $1.03 Million
Q4 2019 Feb 06, 2020	SELL	$166.71 - $223.91 $33,508 - $45,005	-201 Reduced 4.57%	4,200 $920,000
Q3 2019 Oct 29, 2019	SELL	$166.23 - $187.09 $22,274 - $25,070	-134 Reduced 2.95%	4,401 $746,000
Q2 2019 Aug 29, 2019	SELL	$164.61 - $190.37 $8,395 - $9,708	-51 Reduced 1.11%	4,535 $832,000
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $5,730 - $6,814	35 Added 0.77%	4,586 $844,000
Q4 2018 Feb 15, 2019	BUY	$151.91 - $192.21 $293,945 - $371,926	1,935 Added 73.97%	4,551 $754,000
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $438,781 - $504,207	2,616 New	2,616 $504,000

Others Institutions Holding VRTX

# of Institutions

1,624

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hancock Whitney Corp, based on Form 13F filings with the SEC.

News

Stay updated on Hancock Whitney Corp with notifications on news.

Account

Hancock Whitney Corp Vertex Pharmaceuticals Inc Transaction History